S Takaya

Author PubWeight™ 52.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990 5.01
2 Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol 1999 3.75
3 The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991 3.14
4 Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc 1991 2.59
5 A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991 2.49
6 One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991 2.10
7 Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet 1986 2.00
8 The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 1991 1.60
9 A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992 1.50
10 Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation 1992 1.45
11 Neurologic complications of FK 506. Transplant Proc 1991 1.34
12 Evidence that host size determines liver size: studies in dogs receiving orthotopic liver transplants. Hepatology 1987 1.30
13 The clinical significance of the arterial ketone body ratio as an early indicator of graft viability in human liver transplantation. Transplantation 1991 1.24
14 Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1993 1.18
15 Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992 1.09
16 The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991 1.08
17 Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993 1.03
18 Can adenine nucleotides predict primary nonfunction of the human liver homograft? Transpl Int 1994 0.95
19 Respirator-fit testing: does it ensure the protection of healthcare workers against respirable particles carrying pathogens? Infect Control Hosp Epidemiol 2008 0.87
20 Different deviation patterns of carbohydrate-metabolizing enzymes in primary rat hepatomas induced by different chemical carcinogens. Cancer Res 1978 0.83
21 Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc 1991 0.83
22 Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995 0.83
23 Myocardial protection of the pressure overload hypertrophied heart in human cardiac surgery by acceleration of anaerobic glycolysis. J Cardiovasc Surg (Torino) 2002 0.82
24 Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 1989 0.82
25 Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc 1991 0.81
26 A case of early-stage primary malignant melanoma of the esophagus. Gastrointest Endosc 2001 0.81
27 Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc 1991 0.80
28 FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991 0.80
29 Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. Transplant Proc 1992 0.79
30 Effluent levels of hyaluronic acid can predict ultimate graft outcome after clinical liver transplantation: a prospective series. Transplant Proc 1993 0.78
31 Assessment of graft viability using hyaluronic acid and adenosine triphosphate in orthotopic liver transplantation from non-heart-beating donors. Transplant Proc 2000 0.78
32 Enzyme alteration in skeletal muscle of mice with muscular dystrophy. Biochim Biophys Acta 1977 0.78
33 Rat hyperplastic hepatic nodules and primary hepatomas retaining abnormally high pyruvate kinase L type activity. Enzyme 1979 0.78
34 Central antinociceptive effect of L-ornithine, a metabolite of L-arginine, in rats and mice. Eur J Pharmacol 1996 0.77
35 Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. Transplant Proc 1992 0.77
36 [A case of squamous cell carcinoma of the lung associated with exophthalmos and hypercalcemia]. Kyobu Geka 1998 0.77
37 Glomerular endothelial changes in cyclosporine A-treated rats: scanning and transmission electron microscopic studies. Jpn J Surg 1991 0.76
38 Molecular diagnosis of infections in the new millennium. CMAJ 1999 0.76
39 CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplant Proc 1991 0.75
40 Hyaluronate levels in donor organ washout effluents: a simple and predictive parameter of graft viability. Liver 1996 0.75
41 Effect of a stable analogue of prostacyclin on cyclosporine A-induced nephrotoxicity: morphological qualitative and quantitative studies. Transplant Proc 1988 0.75
42 [A case of Terson's syndrome with an interesting MRI finding]. No Shinkei Geka 2000 0.75
43 [A case of pineal teratoma with intraventricular free fat seen in CT scan]. No Shinkei Geka 1986 0.75
44 [A new instrument for insertion of anvil head for circular stapled anastomosis]. Kyobu Geka 2001 0.75
45 [Orthoptic use of bemegride in 3 cases of exotropia]. Nihon Ganka Kiyo 1967 0.75
46 Can adenine nucleotides predict primary nonfunction of the human liver homograft? Transplant Proc 1993 0.75
47 [A case of inflammatory pseudotumor of the lung with suppressed immune response in the patient with renal cell carcinoma after nephrectomy and administration of interferon]. Kyobu Geka 1996 0.75
48 [Nutritional support in cardiac cachexia]. Nihon Rinsho 2001 0.75
49 Role of endothelium for tissue damage by active oxygen radicals in heart-lung transplantation. Transplant Proc 1993 0.75
50 Effect of prostacyclin and glycoprotein IIb/IIIa inhibitor on hyperacute rejection in a rabbit-to-dog lung xenotransplant model. Transplant Proc 2003 0.75
51 [Benefits of 0.5T MR diffusion-weighted images for super-acute-phase cerebral infarction]. No Shinkei Geka 2000 0.75
52 [Results of 43 patients treated by modified radical mastectomy with partial resection of the major pectoral muscle (author's transl)]. Kyobu Geka 1981 0.75
53 [Treatment of nystagmic amblyopia with neuro-psychotropic drugs. II. Diazepam (cercine)]. Nihon Ganka Kiyo 1966 0.75
54 [Surgical treatment of infectious endocarditis complicated by discrete subaortic stenosis: report of a case]. Kyobu Geka 2001 0.75
55 Leukocyte-endothelial interaction: effect of reactive metabolite scavenger. Transplant Proc 1993 0.75
56 [Modified bentall operation using composite graft without resection of aortic valve]. Kyobu Geka 2002 0.75
57 [Childbirth by traditional birth attendants in a remote island of Okinawa]. Nihon Koshu Eisei Zasshi 1995 0.75
58 [Residual symptoms after microvascular decompression for trigeminal neuralgia previously treated by percutaneous nerve blocking]. Neurol Med Chir (Tokyo) 1988 0.75
59 [Report of a successful case of giant congenital bronchogenic cyst with shock due to massive bleeding in the cyst (author's transl)]. Kyobu Geka 1980 0.75
60 Replacement of the canine inferior vena cava with a seeded graft. Surg Today 2001 0.75
61 [An adult case of Bochdalek hernia without an obvious cause; report of a case]. Kyobu Geka 2002 0.75
62 Ascending aorta-bilateral femoral arteries bypass via preperitoneal route of ventral abdominal wall. Nihon Geka Hokan 1984 0.75
63 [Congenital esophagobronchial fistula treated with thoracoscopic assisted surgery]. Kyobu Geka 2003 0.75